United Kingdom prices

The triple salt is better known by the trademarks Caroat (Degussa), OXONE Monopersulfate Compound (Du Pont), and Curox (Laporte). It is also known as potassium caroate. It has been made on a commercial scale siace the 1950s, and the world market ia 1994 was several thousand tons. It is made commercially by Peroxid-Chemie (Germany), Degussa (Germany), Du Pont (United States), and Migas (Japan). In 1994, the United Kingdom price was J1.80/kg ( 2.67/kg). 

Price category production, departmental, institutional Platforms Linux, Alpha, Cray, Fujitsu, AIX, SGI, Sun, HP-UX, NEC Contact information P. J. Knowles School of Chemistry University of Birmingham Edgbaston, Birmingham, B15 2TT United Kingdom +44-121-414-7472 http / / ww w. tc.bham. ac. uk/molpro/ molpro-request tc.bham.ac.uk... 

Historically, the annual consumption of nickel fluoride was on the order of a few metric tons. Usage is droppiag because nickel fluoride is Hsted ia the EPA and TSCA s toxic substance iaventory. Nickel fluoride tetrahydrate is packaged ia 200—500-lb (90.7—227-kg) dmms and the 1993 price was 22/kg. Small quantities for research and pilot-plant work are available from Advance Research Chemicals, Aldrich Chemicals, Johnson/Matthey, Pfalt2 and Bauer, PCR, and Strem Chemicals of the United States, Fluorochem of the United Kingdom, and Morita of Japan. 

Calcium peroxide is made by EMC, L Air Liquide, Nippon Peroxide (Japan), Shimakyo Chemical (Japan), Solvay Deutschland, Solvay Interox (United Kingdom), and Tomita Seiyaku (Japan). Trade names used for calcium peroxide are Calper, IXPER 60 C, IXPER 75 C, PermeOx, and Trap2ene. The world market for calcium peroxide ia 1992 was about 2000 t. The U.S. prices ia 1994 were, for the food-grade (75% Ca02), 3.97/kg and for the technical grade (60%), 2.97—3.30/kg. 

The world market in 1993 was about 450,000 t. Sodium peroxoborate is made commercially by Atochem, Ausimont, Caffaro, Degussa, Eka Nobel, Foret, L Air Liquide, Solvay Interox (Belgium, Italy, Germany, United Kingdom, United States), and Treibacher Chemische Werke. The U.S. price in 1994 was in the range 1.32—1.43/kg, the German price was DM 1.35—1.60/kg ( 0.78—0.92/kg). 

Sales of thiophene in the 1990s amount to hundreds of metric tons per year. SuppHes are available worldwide from Synthetic Chemicals Ltd. (SCL) in the United Kingdom and Elf-Atochem SA in France. There is currendy no U.S. producer of thiophene or the principal thiophene derivatives. At these levels of demand, material is shipped in 200-hter dmms and in bulk quantities. Market price is dependent on the level of off-take. 3-Methylthiophene is also available from SCL, but demand is low and even lower in the case of 2-methylthiophene lower production and lower market demand have led to higher prices for these derivatives. 

Wholesale prices for No. 1 castor oil in tank car lots was l.ll/kg in 1990 compared to 1.60/kg in 1984 and 0.74/kg in 1986 (65). Brazil, China, and India accounted for about 85% of the world exports, and France, the United States, Russia, Germany, and the United Kingdom accounted for about 75% of the world imports from 1986—1989. 

Japan, as of January 1, 1989, had a total capacity of 28 thousand metric tons of monochlorobenzene and 49 thousand tons of dichlorobenzenes. The Japanese prices have remained fairly constant since 1985. The Japanese consumption of -dichlorobenzene is 81% for moth control, 11% for PPS resins, and 8% for dye-stuffs. There has been very Htde export from Japan of chlorobenzenes and imports have been mainly -dichlorobenzene from the United States, Germany, Prance, and the United Kingdom. 

Each Member State of the European Union operates its own policy regarding the pricing of pharmaceutical products. In the United Kingdom, the primary tool is the Pharmaceutical Price Regulation Scheme (PPRS), which is better described as a profit-regulating scheme. This is dealt with in detail in Chapter 26. 

The prices of medicines sold to the NHS are controlled in the United Kingdom by the PPRS, negotiated periodically every 5 to 6 years by the DoH with the Association of the British Pharmaceutical Industry (ABPI), for example in 1979, 1986, 1993 and 1999. The PPRS controls the maximum - but not guaranteed - profits that pharmaceutical companies make on the capital they have invested in plant for research, development and manufacturing for sales made to the NHS. (Capital employed by the individual companies... 

New products introduced following a major apphcation for a product licence from the United Kingdom Licensing Authority may be priced at the discretion of the company on entering the market. This will have to take account of costs of research and development and the competition in the marketplace. 

The United Kingdom is seen from these figures to be a country with a comparatively low per-capita consumption of medicines, to have a high medicines price index and a strong pharmaceutical research base, therefore the various measures to contain medicines expenditure would appear to have had their greatest impact on the demand side. 

The precise role of economic evaluation varies among countries. In the vast majority of jurisdictions the role is confined to decisions about pharmaceuticals only, although the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom also considers devices, medical procedures, and public health interventions. Even among those countries considering only pharmaceuticals, there are variations in policy. In some, all new pharmaceuticals are considered, whereas in others only those drugs having a premium price, or likely to have a major impact on the health care system, are evaluated. 

Third, economic data are more important when there is substantial budgetary impact. In some jurisdictions, technologies are selected for appraisal only if they have a substantial impact on the (national) health service (e.g., in the United Kingdom), or if the manufacturer wants a premium price over other drugs to treat the given health condition (e.g., in the Netherlands). In addition, in several countries the authorities require an estimation of overall budgetary impact as well as the incremental cost-effectiveness ratio. 

---